The FreeStyle Libre system is manufactured by Abbott in Witney, Oxfordshire, UK. As manufacturing is scaled up to meet UK and global demand, increased investment and jobs are being created on the site in the UK.
Abbott has also invested in and completed two large clinical trials in Type 1 and Type 2 patients who intensively use insulin to demonstrate value to payers that patients and physicians are experiencing with FreeStyle Libre system1,2.
To give people with Diabetes in the UK who are on Intensive Insulin therapy and have to test blood glucose multiple times per day access, Abbott is actively pursuing reimbursement. An application has been submitted to the NHS Business Service Authority to have FreeStyle Libre flash glucose monitoring system sensor assessed for listing in the NHS England and Wales Drug Tariff for multiple daily injectors of insulin (MDIs) and available on prescription in the community (FP10), which was acknowledged by them in June 2016. The NHS Business Service Authority will be following the procedures agreed between the Department of Health and the Drug Tariff Part IX Forum and the submission is being processed according to the date order in which it was received. Additionally, we are also pursuing reimbursement in Scotland and Northern Ireland with the appropriate bodies.
1. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Bolinder, Jan et al. The Lancet , Volume 388 , Issue 10057 , 2254 – 2263.
2. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. Haak, T., Hanaire, H., Ajjan, R. et al. Diabetes Ther (2016). doi:10.1007/s13300-016-0223-6.